29 EMMONS DRIVE, PRINCETON, NJ
Market cap: $11.3M (2/09/2026)
Price: $1.12
Soligenix, Inc. Enters At Market Issuance Sales Agreement for $3.45M
Soligenix Regains Compliance with Nasdaq Shareholders' Equity Requirement
Material Contracts, Other Events
FDA Grants Orphan Drug Designation for the Treatment of Behçet’s Disease after Reviewing Recent Phase 2 Clinical Study Results
News
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the Treatment of Behçet’s Disease
News, Material Contracts
Annual Report to Security Holders
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload